Clinical trials: Myelofibrosis (MF)
Secondary AML, Myelofibrosis
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
The purpose of this study is to test the safest and most effective dose of a new investigational drug, rebecsinib. Participants in this study will have either Secondary Acute Myeloid Leukemia (sAML) that has either returned…
- Trial name
- NCT07250646
- Testing
- rebecsinib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Aspera Biomedicines, Inc.
Luspatercept, Poor Erythroid Engraftment
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important treatment for hematological malignancies. Poor erythroid engraftment after transplantation is a serious complication, especially in patients with…
- Conditions
- Luspatercept, Poor Erythroid Engraftment, Hematological Malignancies, Myelofibrosis (MF)
- Trial name
- NCT07539779
- Testing
- Luspatercept, Control
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Nanfang Hospital, Southern Medical University